The Technical Analyst
Select Language :
GlycoMimetics Inc [GLYC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

GlycoMimetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

GlycoMimetics Inc is listed at the  Exchange

-5.66% $3.00

America/New_York / 28 mar 2024 @ 16:00


GlycoMimetics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 193.18 mill
EPS: -0.630
P/E: -4.76
Earnings Date: Apr 30, 2024
SharesOutstanding: 64.39 mill
Avg Daily Volume: 0.346 mill
RATING 2024-03-28
B+
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -4.76 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.81x
Company: PE -4.76 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.647
(-78.43%) $-2.35
Date: 2024-03-29
Expected Trading Range (DAY)

$ 2.78 - 3.24

( +/- 7.57%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-01-12 Johnson Bruce S Buy 250 000 Employee Stock Option (right to buy)
2024-01-12 Semerjian Harout Buy 695 000 Employee Stock Option (right to buy)
2024-01-12 Rock Edwin Buy 250 000 Employee Stock Option (right to buy)
2024-01-12 Rath Chinmaya Buy 250 000 Employee Stock Option (right to buy)
2024-01-12 Hahn Brian M. Buy 250 000 Employee Stock Option (right to buy)
INSIDER POWER
24.64
Last 98 transactions
Buy: 7 242 922 | Sell: 5 299 394

Forecast: 16:00 - $3.02

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.02
Forecast 2: 16:00 - $3.02
Forecast 3: 16:00 - $3.02
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.00 (-5.66% )
Volume 0.648 mill
Avg. Vol. 0.346 mill
% of Avg. Vol 187.15 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for GlycoMimetics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for GlycoMimetics Inc

RSI

Intraday RSI14 chart for GlycoMimetics Inc

Last 10 Buy & Sell Signals For GLYC

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            GlycoMimetics Inc

GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Last 10 Buy Signals

Date Signal @
HBTCUSDMar 29 - 04:3834 558
DESOUSDMar 29 - 04:3931.41
ARUSDMar 29 - 04:28$41.19
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.